Cannabis Law Report

JUNE 10, 2021

Studies of crash or driving data suggest that, although permissive marijuana policies are associated with higher prevalence of tetrahydrocannabinol (THC) presence among drivers [ 1 , 2 ], there is mixed evidence that these policies are associated with motor vehicle crashes [ 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. never vs. at least once). (2)

Policy 59

Policy Safety Marijuana Data 59

Green Relief

MAY 13, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. In 2002, the Journal of Neuroscience reported that the impact of induced cerebral ischemia is much more severe in CB1 knockout mice than in “wild type” mice with cannabinoid receptors.

THC 64

THC CBD Cannabinoids Research and Development 64

Green Relief

MAY 12, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. In 2002, the Journal of Neuroscience reported that the impact of induced cerebral ischemia is much more severe in CB1 knockout mice than in “wild type” mice with cannabinoid receptors.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 2002 Jun;42(8):993-1007.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Politicians, policymakers, and legislators are important audiences who are influenced and, of course, specifically targeted by medical journals (Stryker 2002 ). Data collection. This offers a more denotative approach to complement the data.

Research and Development 52

Research and Development Medicine Access Media 52